Nuvectis Pharma Inc Cash Flow-to-Debt Ratio
Nuvectis Pharma Inc cash flow-to-debt ratio. Nuvectis Pharma Inc (NVCT) has a Cash Flow-to-Debt Ratio of -0.34x as of June 2026, meaning its operating cash flow of $-4.53 Million could theoretically repay 0% of its total liabilities ($13.29 Million) in one year. See Nuvectis Pharma Inc financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Nuvectis Pharma Inc (2020–2025)
Cash flow-to-debt ratio of Nuvectis Pharma Inc from 2020 to 2025. Historical debt coverage capacity for Nuvectis Pharma Inc across 6 annual periods. Check cash flow reinvestment rate of Nuvectis Pharma Inc to assess the company's total reinvestment commitment from operating cash flow.
Nuvectis Pharma Inc Cash Flow-to-Debt Ratio by Year (2020–2025)
Nuvectis Pharma Inc cash flow-to-debt ratio by year from 2020 to 2025. Year-by-year debt coverage analysis for Nuvectis Pharma Inc. For the full cash flow conversion analysis, see NVCT cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.20x | $-16.01 Million | $13.30 Million | ▲ +12.6% |
| 2024 | -1.38x | $-12.25 Million | $8.89 Million | ▲ +39.7% |
| 2023 | -2.28x | $-15.95 Million | $6.98 Million | ▼ -4.2% |
| 2022 | -2.19x | $-13.56 Million | $6.19 Million | ▼ -307.4% |
| 2021 | -0.54x | $-9.50 Million | $17.66 Million | ▼ -122.4% |
| 2020 | 2.40x | $24.00K | $10.00K | — |